Can chemoprevention reduce the risk of progression to malignancy?
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Responses are now closed for this article.
G S H has acted as a consultant to AstraZeneca, Novartis and Pharmacia (Pfizer), and has received research support, sponsored travel and honoraria for speaking from AstraZeneca, Novartis and Wyeth. S N has acted in an advisory capacity to Pharmacia and has received research support, sponsored travel and honoraria for speaking from AstraZeneca and Pharmacia (Pfizer).